Member Info for Toukankahmoon

Ginge

Everyone has different investment aims. I only caution falling in love with a single share and all that that means. And however good it sounds do not fall for the hype. Always keep your risk/reward analysis up to date. Never invest more than you can afford to lose no matter how much of a slam dunk the investment seems.

Sermon ends. Good Luck.

Apologies. All this hypothetical carp bores me. I just want decent AVA6000 clinical efficacy data. And a hint of how FPD in AVA6103 is getting on. March 31st + 12 weeks = ???

Thompi

Thanks. I was confused by the title in the link

“Preliminary Results for the year ended December 31, 2025”

But because you are prepared to be helpful and not an arse like some others , I can now see what BenH was talking about. Thanks

Mea culpa

Apologies BenH

Let’s hope that these discussions under NDA reach a speedy and successful conclusion.

Lovable

That’s what we all hope. But AVA6000 doesn’t seem to have high enough efficacy rates.

CJ62

If you used your brain and precious time to take an objective view of what is going on rather than continual spiteful character assassinations, then this BB would be a better place.

To my mind, and I stated this a year ago, the biggest threat to commercialisation of AVA6000 is AVA 6103 and other 2nd generation drugs that could use other warheads including doxorubicin as a warhead. There is a reason why Avacta focus moved away from AVA6000 a year ago.

Why would BP pay huge sums to develop AVA6000 which has inconsistent results when a much better drug is only a couple of years behind it????

Platform works but that isn’t going to help commercialise AVA6000

Tim

Thompi’s reference is from December 25.

Give the link to the session you are talking about please pretty please instead of just smart arse jibes

To my mind, and I stated this a year ago, the biggest threat to commercialisation of AVA6000 is AVA 6103 and other 2nd generation drugs that could use other warheads including doxorubicin as a warhead. There is a reason why Avacta focus moved away from AVA6000 a year ago.

Why would BP pay huge sums to develop AVA6000 which has inconsistent results when a much better drug is only a couple of years behind it????

Thompi

Thanks I hadn’t gone that far back. I thought BenH was referring to some recent comments from CC on NDAs.

Thanks Tim. Helpful as ever

Benh

Just tried to find Q&A in question. Can you humour me by telling me where I can find it or posting a link. This isn’t a wind up. I genuinely want to see it because there msybe other stuff I’m not aware of.

Thanks in advance

. . . I think it’s because the rampers keep trotting out encouraging words such as “fill your boots we’ll never buy at these prices again “. Even today someone greeted the fall in SP as another great buying opportunity. We don’t want that, what we want is a selling opportunity. 😁

BenH

You are insane

Rampers have been saying for years that Avacta cannot tell us how marvellous they are because of NDAs. And it’s never been true.

IceCool

With the continual explanations of the science, you are surprised at the safety profile? Give me strength. To quote previous posts- it can be as safe as Ribena but if it’s not efficacious enough, no one will buy it? How long has this trial been going on. And yet the rampers still think it was a great RNS. Mind you they state with huge pride that every Avacta RNS is a great RNS. Unfortunately the market frequently doesn’t agree and for the moment neither does BP.

We know all this.

We were expecting some decent efficacy results.

Yes rampers I know it’s phase1 but come on Avacta let’s have some transparency here.

BV

The whole mystery is about at which conference will the transformational bang up to date AVA6000 clinical trial data be released. It seems less likely at a conference where it is just a poster.

That’s all I’m saying.

Publication only

Any post of AI generated text on here needs to include the question that prompted that reply and which LLM was used.

BV

Please provide a link to a source that states that Avacta are presenting.

This BB is full of predictions based on no information.